Candida biofilms: Antifungal resistance and emerging therapeutic options

Current Opinion in Investigational Drugs

Volumn 5, Issue 2, 2004, Pages 186-197

  Kuhn, Duncan M ^a   Ghannoum, Mahmoud A ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antifungal; Biofilm; Candida; Resistance; Treatment

Indexed keywords

ANTIFUNGAL AGENT;

ANIMAL; ANTIBIOTIC RESISTANCE; BIOFILM; CANDIDA; CANDIDIASIS; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS;

EID: 3042761501     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. O'Toole G, Kaplan HB, Kolter R: Biofilm formation as microbial development. Annu Rev Microbiol (2000) 54:49-79.
2. Mah TF, O'Toole GA: Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol (2001) 9(1):34-39.
3. Brown WJ: Microbiology of the infected total joint arthroplasty. Semin Arthroplasty (1994) 5(3):107-113.
4. Bauer TT, Torres A, Ferrer R, Heyer CM, Schultze-Werninghaus G, Rasche K: Biofilm formation in endotracheal tubes. Association between pneumonia and the persistence of pathogens. Monaldi Arch Chest Dis (2002) 57(1):84-87.
5. Costerton JW: Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol (2001) 9(2):50-52.
6. Marrie TJ, Costerton JW: Scanning and transmission electron microscopy of in situ bacterial colonization of intravenous and intraarterial catheters. J Clin Microbiol (1984) 19(5):687- 693.
7. Marrie TJ, Costerton JW: The ultrastructure of Candida albicans infections. Can J Microbiol (1981) 27(11):1156-1164.
8. Marrie TJ, Cooper JH, Costerton JW: Ultrastructure of Candida parapsilosis endocarditis. Infect Immun (1984) 45(2):390-398.
9. Marrie TJ, Noble MA, Costerton JW: Examination of the morphology of bacteria adhering to peritoneal dialysis catheters by scanning and transmission electron microscopy. J Clin Microbiol (1983) 18(6):1388-1398.
10. Marrie TJ, Costerton JW: A scanning and transmission electron microscopic study of the surfaces of intrauterine contraceptive devices. Am J Obstet Gynecol (1983) 146(4):384-394.
11. Marrie TJ, Sung JY, Costerton JW: Bacterial biofilm formation on nasogastric tubes. J Gastroenterol Hepatol (1990) 5(5):503-506.
12. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA: Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol (2001) 183(18):5385-5394.
13. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA: Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun (2002) 70(2):878-888.
14. Hawser SP, Douglas LJ: Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (1995) 39(9):2128-2131.
15. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: A common cause of persistent infections. Science (1999) 284(5418):1318- 1322.
16. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA: Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother (2002) 46(6):1773-1780.
17. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, López-Ribot JL: In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother (2002) 46(11):3634-3636.
18. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson J, Henderson T, Martone WJ: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med (1991) 91(3B):86S- 89S.
19. Anaissie EJ, Rex JH, Uzun O, Vartivarian S: Predictors of adverse outcome in cancer patients with candidemia. Am J Med (1998) 104(3):238-245.
20. Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL: Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med (1995) 155(22):2429-2435.
21. Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM, Pizzo PA, Walsh TJ: Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes. Clin Infect Dis (1992) 14(4):875-883.
22. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ: Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother (2000) 44(3):747-751.
23. Lewis RE, Klepser ME: The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy. Am J Health Syst Pharm (1999) 56(6):525-533.
24. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA: Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis (1999) 33(4):217-222.
25. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards JE Jr, Jarvis W, Dawson J, Wenzel RP: National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis (1999) 29(2):253-258.
26. Krcmery V Jr, Kovacicova G: Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: Trends in etiology in 310 episodes. Slovak Fungaemia study group. Diagn Microbiol Infect Dis (2000) 36(1):7-11.
27. Pagano L, Antinori A, Ammassari A, Mele L, Nosari A, Melillo L, Martino B, Sanguinetti M, Equitani F, Nobile F, Carotenuto M et al: Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. Eur J Haematol (1999) 63(2):77-85.
28. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, Blumberg HM, Patterson JE, Rinaldi M, Edwards JE, Wenzel RP et al: Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J (2000) 19(4):319-324.
29. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ: Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. Am J Med (1993) 94(6):577-582.
30. Weems JJ Jr, Chamberland ME, Ward J, Willy M, Padhye AA, Solomon SL: Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol (1987) 25(6):1029-1032.
31. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE: Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis (2001) 32(9):1249-1272.
32. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE: Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 30(4):662-678.
33. Nucci M, Colombo AL, Silveira F, Richtmann R, Salomao R, Branchini ML, Spector N: Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol (1998) 19(11):846-850.
34. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB: Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med (1997) 127(4):275-280.
35. Saad TF: Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis (1999) 34(6):1114-1124.
36. Kovalik EC, Raymond JR, Albers FJ, Berkoben M, Butterly DW, Montella B, Conlon PJ: A clustering of epidural abscesses in chronic hemodialysis patients: Risks of salvaging access catheters in cases of infection. J Am Soc Nephrol (1996) 7(10):2264-2267.
37. Davey ME, O'Toole GA: Microbial biofilms: From ecology to molecular genetics. Microbiol Mol Biol Rev (2000) 64(4):847-867.
38. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL: Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol (2001) 18:157-164.
39. Baillie GS, Douglas LJ: Role of dimorphism in the development of Candida albicans biofilms. J Med Microbiol (1999) 48(7):671-679.
40. Xu KD, Stewart PS, Xia F, Huang CT, McFeters GA: Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability. Appl Environ Microbiol (1998) 64(10):4035-4039.
41. Stoodley P, deBeer D, Lappin-Scott HM: Influence of electric fields and pH on biofilm structure as related to the bioelectric effect. Antimicrob Agents Chemother (1997) 41(9):1876-1879.
42. Wimpenny J, Manz W, Szewzyk U: Heterogeneity in biofilms. FEMS Microbiol Rev (2000) 24(5):661-671.
43. Rasmussen K, Lewandowski Z: Microelectrode measurements of local mass transport rates in heterogeneous biofilms. Biotechnol Bioeng (1998) 59(3):302-309.
44. Chandra J, Mukherjee PK, Leidich SD, Faddoul FF, Hoyer LL, Douglas LJ, Ghannoum MA: Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res (2001) 80(3):903-908.
45. Cowen LE, Sanglard D, Calabrese D, Sirjusingh C, Anderson JB, Kohn LM: Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol (2000) 182(6):1515-1522.
46. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J: Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother (1998) 42(12):3065-3072.
47. Krcmery V, Barnes AJ: Non-albicans Candida spp causing fungaemia: Pathogenicity and antifungal resistance. J Hosp Infect (2002) 50(4):243-260.
48. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 39(1):1-8.
49. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents in Candida albicans iasolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother (1995) 39(11):2378- 2386.
50. Sanglard D, Ischer F, Monod M, Bille J: Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene. Microbiology (1997) 143(2):405-416.
51. Ghannoum MA, Rice LB: Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev (1999) 12(4):501-517.
52. Henry KW, Nickels JT, Edlind TD: Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother (2000) 44(10):2693-2700.
53. White TC, Holleman S, Dy F, Mirels LF, Stevens DA: Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother (2002) 46(6):1704-1713.
54. De Backer MD, Ilyina T, Ma XJ, Vandoninck S, Luyten WH, Vanden Bossche H: Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob Agents Chemother (2001) 45(6):1660-1670.
55. Rogers PD, Barker KS: Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans by cDNA microarray analysis. Antimicrob Agents Chemother (2002) 46(11):3412-3417.
56. Stewart PS, Costerton JW: Antibiotic resistance of bacteria in biofilms. Lancet (2001) 358(9276):135-138.
57. Kuchma SL, O'Toole GA: Surface-induced and biofilm-induced changes in gene expression. Curr Opin Biotechnol (2000) 11(5):429-433.
58. Shigeta M, Tanaka G, Komatsuzawa H, Sugai M, Suginaka H, Usui T: Permeation of antimicrobial agents through Pseudomonas aeruginosa biofilms: A simple method. Chemotherapy (1997) 43(5):340-345.
59. Hoyle BD, Jass J, Costerton JW: The biofilm glycocalyx as a resistance factor. J Antimicrob Chemother (1990) 26(1):1-5.
60. Tresse O, Jouenne T, Junter GA: The role of oxygen limitation in the resistance of agar-entrapped, sessile-like Escherichia coli to aminoglycoside and β-lactam antibiotics. J Antimicrob Chemother (1995) 36(3):521-526.
61. Xu KD, McFeters GA, Stewart PS: Biofilm resistance to antimicrobial agents. Microbiology (2000) 146(3):547-549.
62. Huang CT, Xu KD, McFeters GA, Stewart PS: Spatial patterns of alkaline phosphatase expression within bacterial colonies and biofilms in response to phosphate starvation. Appl Environ Microbiol(1998) 64(4):1526-1531.
63. Kinniment SL, Wimpenny JW: Measurements of the distribution of adenylate concentrations and adenylate energy charge across Pseudomonas aeruginosa biofilms. Appl Environ Microbiol (1992) 58(5):1629-1635.
64. Wentland EJ, Stewart PS, Huang CT, McFeters GA: Spatial variations in growth rate within Klebsiella pneumoniae colonies and biofilm. Biotechnol Prog (1996) 12(3):316-321.
65. Sternberg C, Christensen BB, Johansen T, Toftgaard Nielsen A, Andersen JB, Givskov M, Molin S: Distribution of bacterial growth activity in flow-chamber biofilms. Appl Environ Microbiol (1999) 65(9):4108-4117.
66. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR: Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol (2001) 183(18):5395-5401.
67. Gordon CA, Hodges NA, Marriott C: Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa. J Antimicrob Chemother (1988) 22(5):667-674.
68. Nichols WW, Dorrington SM, Slack MP, Walmsley HL: Inhibition of tobramycin diffusion by binding to alginate. Antimicrob Agents Chemother (1988) 32(4):518-523.
69. Anderl JN, Franklin MJ, Stewart PS: Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother (2000) 44(7):1818-1824.
70. Zahller J, Stewart PS: Transmission electron microscopic study of antibiotic action on Klebsiella pneumoniae biofilm. Antimicrob Agents Chemother (2002) 46(8):2679-2683.
71. Zheng Z, Stewart PS: Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother (2002) 46(3):900-903.
72. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS: Extracellular DNA required for bacterial biofilm formation. Science (2002) 295(5559):1487.
73. Sauer K, Camper AK: Characterization of phenotypic changes in Pseudomonas putida in response to surface-associated growth. J Bacteriol (2001) 183(22):6579-6589.
74. Brown MR, Allison DG, Gilbert P: Resistance of bacterial biofilms to antibiotics: A growth-rate related effect? J Antimicrob Chemother (1988) 22(6):777-780.
75. Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM, Lory S, Greenberg EP: Gene expression in Pseudomonas aeruginosa biofilms. Nature (2001) 413(6858):860-864.
76. Spoering AL, Lewis K: Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol (2001) 183(23):6746-6751.
77. Parsek MR, Greenberg EP: Quorum sensing signals in development of Pseudomonas aeruginosa biofilms. Methods Enzymol (1999) 310:43-55.
78. De Kievit TR, Iglewski BH: Quorum sensing, gene expression, and Pseudomonas biofilms. Methods Enzymol (1999) 310:117-128.
79. Yoon SS, Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K, Kamani MC, Allen HL, DeKievit TR, Gardner PR, Schwab U, Rowe JJ et al: Pseudomonas aeruginosa anaerobic respiration in biofilms: Relationships to cystic fibrosis pathogenesis. Dev Cell (2002) 3(4):593-603.
80. Erickson DL, Endersby R, Kirkham A, Stuber K, Vollman DD, Rabin HR, Mitchell I, Storey DG: Pseudomonas aeruginosa quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. Infect Immun (2002) 70(4):1783-1790.
81. Hentzer M, Riedel K, Rasmussen TB, Heydorn A, Andersen JB, Parsek MR, Rice SA, Eberl L, Molin S, Hoiby N, Kjellebergs S et al: Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology (2002) 148(1):87-102.
82. Cripps AW, Dunkley ML, Taylor DC, Cousins S, Clancy RL: Immunity to Pseudomonas aeruginosa induced by OprF following intestinal immunization. Adv Exp Med Biol (1995) 371B:761-763.
83. Price BM, Barten Legutki J, Galloway DR, von Specht BU, Gilleland LB, Gilleland HE Jr, Staczek J: Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa. FEMS Immunol Med Microbiol (2002) 33(2):89-99.
84. Zimmermann K, Bernhardt J, Knoke M, Bernhardt H: Influence of voriconazole and fluconazole on Candida albicans in long-time continuous flow culture. Mycoses (2002) 45(Suppl 1):41-46.
85. Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL: The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett (2002) 214(1):95-100.
86. Ramage G, Wickes BL, Lopez-Ribot JL: Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab (2001) 20(7):42-44.
87. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA: Mechanism of fluconazole resistance in Candida albicans biofilms: Phase-specific role of efflux pumps and membrane sterols. Infect Immun (2003) 71(8):4333-4340.
88. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL: Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother (2002) 49(6):973-980.
89. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ: Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): A 91-day study in rats. Pharm Res (2000) 17(12):1494-1502.
90. Al-Adham IS, Al-Hmoud ND, Khalil E, Kierans M, Collier PJ: Microemulsions are highly effective anti-biofilm agents. Lett Appl Microbiol (2003) 36(2):97-100.
91. Al-Adham IS, Khalil E, Al-Hmoud ND, Kierans M, Collier PJ: Microemulsions are membrane-active, antimicrobial, self-preserving systems. J Appl Microbiol (2000) 89(1):32-39.
92. Trull AK, Tan KK, Tan L, Alexander GJ, Jamieson NV: Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion. Transplant Proc (1994) 26(5):2977-2978.
93. Jessup C, Reyes G, Fothergill A, McCarthy D, Rinaldi M, Messer S, Pfaller M, Ghannoum M: A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: A multicenter study. J Chemother (2000) 12(1):22-29.
94. Andriole VT: The 1998 Garrad Lecture. Current and future antifungal therapy: New targets for antifungal agents. J Antimicrob Chemother (1999) 44(2):151-162.
95. Lewis K: Riddle of biofilm resistance. Antimicrob Agents Chemother (2001) 45(4):999-1007.
96. Singh PK, Parsek MR, Greenberg EP, Welsh MJ: A component of innate immunity prevents bacterial biofilm development. Nature (2002) 417(6888):552-555.
97. Wakabayashi H, Takakura N, Teraguchi S, Tamura Y: Lactoferrin feeding augments peritoneal macrophage activities in mice intraperitoneally injected with inactivated Candida albicans. Microbiol Immunol (2003) 47(1):37-43.
98. Nikawa H, Samaranayake LP, Tenovuo J, Pang KM, Hamada T: The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch Oral Biol (1993) 38(12):1057-1063.
99. Zasloff M: Antimicrobial peptides of multicellular organisms. Nature (2002) 415(6870):389-395.
100. Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P, Nickerson KW: Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol (2001) 67(7):2982-2992.
101. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL: Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol (2002) 68(11):5459-5463.
102. Huang CT, Stewart PS: Reduction of polysaccharide production in Pseudomonas aeruginosa biofilms by bismuth dimercaprol (BisBAL) treatment. J Antimicrob Chemother (1999) 44(5):601-605.
103. Matthews R, Burnie J: Antifungal antibodies: A new approach to the treatment of systemic candidiasis. Curr Opin Investig Drugs (2001) 2(4):472-476.
104. Krishnasami Z, Carlton D, Bimbo L, Taylor ME, Balkovetz DF, Barker J, Allon M: Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int (2002) 61(3):1136-1142.
105. Shah CB, Mittelman MW, Costerton JW, Parenteau S, Pelak M, Arsenault R, Mermel LA: Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother (2002) 46(6):1674-1679.
106. Mermel LA: Prevention of intravascular catheter-related infections. Ann Intern Med (2000) 132(5):391-402.
107. Raad II: The pathogenesis and prevention of central venous catheter-related infections. Middle East J Anesthesiol (1994) 12(4):381-403.
108. Marion-Ferey K, Pasmore M, Stoodley P, Wilson S, Husson GP, Costerton JW: Biofilm removal from silicone tubing: An assessment of the efficacy of dialysis machine decontamination procedures using an in vitro model. J Hosp Infect (2003) 53(1):64-71.
109. Costerton JW, Ellis B, Lam K, Johnson F, Khoury AE: Mechanism of electrical enhancement of efficacy of antibiotics in killing biofilm bacteria. Antimicrob Agents Chemother (1994) 38(12):2803-2809.
110. Wellman N, Fortun SM, McLeod BR: Bacterial biofilms and the bioelectric effect. Antimicrob Agents Chemother (1996) 40(9):2012-2014.
111. Jass J, Costerton JW, Lappin-Scott HM: The effect of electrical currents and tobramycin on Pseudomonas aeruginosa biofilms. J Ind Microbiol (1995) 15(3):234-242.
112. Liu WK, Tebbs SE, Byrne PO, Elliott TS: The effects of electric current on bacteria colonising intravenous catheters. J Infect (1993) 27(3):261-269.
113. Stewart PS, Wattanakaroon W, Goodrum L, Fortun SM, McLeod BR: Electrolytic generation of oxygen partially explains electrical enhancement of tobramycin efficacy against Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother (1999) 43(2):292-296.
114. Rediske AM, Roeder BL, Brown MK, Nelson JL, Robison RL, Draper DO, Schaalje GB, Robison RA, Pitt WG: Ultrasonic enhancement of antibiotic action on Escherichia coli biofilms: An in vivo model. Antimicrob Agents Chemother (1999) 43(5):1211-1214.
115. O'Neill JF, Hope CK, Wilson M: Oral bacteria in multi-species biofilms can be killed by red light in the presence of toluidine blue. Lasers Surg Med (2002) 31(2):86-90.
116. Greenfeld JI, Sampath L, Popilskis SJ, Brunnert SR, Stylianos S, Modak S: Decreased bacterial adherence and biofilm formation on chlorhexidine and silver sulfadiazine-impregnated central venous catheters implanted in swine. Crit Care Med (1995) 23(5):894-900.
117. Bassetti S, Hu J, D'Agostino RB Jr, Sherertz RJ: Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo. Antimicrob Agents Chemother (2001) 45(5):1535-1538.
118. Heard SO, Wagle M, Vijayakumar E, McLean S, Brueggemann A, Napolitano LM, Edwards LP, O'Connell FM, Puyana JC, Doern GV: Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med (1998) 158(1):81-87.
119. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD: Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: A meta-analysis. J Am Med Assoc (1999) 281(3):261-267.
120. Bechert T, Boswald M, Lugauer S, Regenfus A, Greil J, Guggenbichler JP: The Erlanger silver catheter: In vitro results for antimicrobial activity. Infection (1999) 27(Suppl 1):S24-S29.
121. Illingworth B, Bianco RW, Weisberg S: In vivo efficacy of silver-coated fabric against Staphylococcus epidermidis. J Heart Valve Dis (2000) 9(1):135-141.
122. Hannan M, Juste RN, Umasanker S, Glendenning A, Nightingale C, Azadian B, Soni N: Antiseptic-bonded central venous catheters and bacterial colonisation. Anaesthesia (1999) 54(9):868-872.
123. Veenstra DL, Saint S, Sullivan SD: Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. J Am Med Assoc (1999) 282(6):554-560.
124. Dijk F, Westerhof M, Busscher HJ, van Luyn MJ, van Der Mei HC: In vitro formation of oropharyngeal biofilms on silicone rubber treated with a palladium/tin salt mixture. J Biomed Mater Res (2000) 51(3):408-412.
125. Imbert C, Lassy E, Daniault G, Jacquemin JL, Rodier MH: Treatment of plastic and extracellular matrix components with chlorhexidine or benzalkonium chloride: Effect on Candida albicans adherence capacity in vitro. J Antimicrob Chemother (2003) 51(2):281-287.
126. Everaert EP, Mahieu HF, van de Belt-Gritter B, Peeters AJ, Verkerke GJ, van der Mei HC, Busscher HJ: Biofilm formation in vivo on perfluoro-alkylsiloxane-modified voice prostheses. Arch Otolaryngol Head Neck Surg (1999) 125(12):1329-1332.
127. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. National Committee for Clinical Laboratory Standards (1997): Approved standard NCCLS document M27-A.